1666PD - Trilaciclib (T) decreases multi-lineage myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy
| Autor: | Dragnev, K.H., Owonikoko, T.K., Csoszi, T., Maglakelidze, M., Beck, J.T., Domine Gomez, M., Lowczak, A., Fulop, A., Hoyer, R.J., Hanna, W., Lowry, P., Aljumaily, R., Chiu, V.K., Bulat, I., Yang, Z., Roberts, P.J., Antal, J.M., Malik, R.K., Morris, S.R., Weiss, J.M. |
|---|---|
| Zdroj: | In Annals of Oncology October 2018 29 Supplement 8 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|